Program
Allogeneic BAFF-L-expressing CAR T Cells LMY-922
Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin, led by Luminary Therapeutics.
Furthest: phase 1, since Jun 22, 20262 company-led studies, 2 open or runningNext primary completion: Apr 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Luminary Therapeutics | 22 open or running | phase 1since Jun 22, 2026 | Jun 22, 2026 | Apr 2029phase 1 · NCT07679919 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 22, 2026First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT07679919 · 27 planned · United States
- Jul 15, 2026Phase 1 study in Arthritis, RheumatoidNCT07729995 · 94 planned · United States
Ahead
- Apr 2029Primary completion: phase 1 study in Lymphoma, Non-HodgkinNCT07679919
- Mar 2030Primary completion: phase 1 study in Arthritis, RheumatoidNCT07729995
TargetBeta
CD4 →read by rule
“A preparation of allogeneic cluster of differentiation 4 (CD4)-positive and CD8-positive, gamma/delta-specific, T-lymphocytes that are genetically engineered, using the non-viral transposon system, to express a chimeric antigen receptor (CAR) expressing the B-cell activation factor ligand (BAFF-L) a”NCIt, by rule
Other programs on CD4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
| VRC07-523LSrule | taimed-biologics-inc | phase 2 | 3 |
| TMB-365rule | taimed-biologics-inc | phase 2 | 3 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07729995Arthritis, Rheumatoid · United States | 1 | Not yet recruiting | Mar 2030 | 94 |
| NCT07679919Lymphoma, Non-Hodgkin · United States | 1 | Not yet recruiting | Apr 2029 | 27 |
How it is read
Names in the registry
- “LMY-922”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.